Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition.
Rimassa L, Bozzarelli S, Pietrantonio F, Cordio S, Lonardi S, Toppo L, Zaniboni A, Bordonaro R, Di Bartolomeo M, Tomasello G, Dadduzio V, Tronconi MC, Piombo C, Giordano L, Gloghini A, Di Tommaso L, Santoro A. Rimassa L, et al. Among authors: bozzarelli s. Clin Colorectal Cancer. 2019 Jun;18(2):125-132.e2. doi: 10.1016/j.clcc.2019.02.004. Epub 2019 Feb 14. Clin Colorectal Cancer. 2019. PMID: 30846365 Clinical Trial.
Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma.
Santoro A, Pressiani T, Citterio G, Rossoni G, Donadoni G, Pozzi F, Rimassa L, Personeni N, Bozzarelli S, Rossoni G, Colombi S, De Braud FG, Caligaris-Cappio F, Lambiase A, Bordignon C. Santoro A, et al. Among authors: bozzarelli s. Br J Cancer. 2010 Sep 7;103(6):837-44. doi: 10.1038/sj.bjc.6605858. Epub 2010 Aug 17. Br J Cancer. 2010. PMID: 20717115 Free PMC article. Clinical Trial.
A phase II randomized dose escalation trial of sorafenib in patients with advanced hepatocellular carcinoma.
Rimassa L, Pressiani T, Boni C, Carnaghi C, Rota Caremoli E, Fagiuoli S, Foa P, Salvagni S, Cortesi E, Chiara Tronconi M, Personeni N, Bozzarelli S, Chiara Banzi M, Fanello S, Romano Lutman F, Giordano L, Santoro A. Rimassa L, et al. Among authors: bozzarelli s. Oncologist. 2013;18(4):379-80. doi: 10.1634/theoncologist.2012-0221. Epub 2013 Apr 11. Oncologist. 2013. PMID: 23580239 Free PMC article. Clinical Trial.
FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study.
Personeni N, Rimassa L, Verusio C, Barni S, Rubino L, Bozzarelli S, Villa E, Carnaghi C, Tronconi MC, Gerardi C, Galli F, Floriani I, Destro A, Raschioni C, Labianca R, Santoro A. Personeni N, et al. Among authors: bozzarelli s. Clin Colorectal Cancer. 2015 Sep;14(3):162-9. doi: 10.1016/j.clcc.2015.02.006. Epub 2015 Mar 6. Clin Colorectal Cancer. 2015. PMID: 25861836 Clinical Trial.
A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer.
Pietrantonio F, Aprile G, Rimassa L, Franco P, Lonardi S, Cremolini C, Biondani P, Sbicego EL, Pasqualetti F, Tomasello G, Niger M, Casagrande M, Ghidini M, Muni R, Montrone S, Bergamo F, Berenato R, Fontanella C, Bozzarelli S, Moretto R, Battaglin F, Di Bartolomeo M, de Braud F, Miceli R. Pietrantonio F, et al. Among authors: bozzarelli s. Radiother Oncol. 2015 Nov;117(2):315-21. doi: 10.1016/j.radonc.2015.08.023. Epub 2015 Sep 4. Radiother Oncol. 2015. PMID: 26347495
KRAS mutation in lung metastases from colorectal cancer: prognostic implications.
Ghidini M, Personeni N, Bozzarelli S, Baretti M, Basso G, Bianchi P, Tronconi MC, Pressiani T, Grizzi F, Giordano L, Malesci A, Alloisio M, Laghi L, Santoro A, Rimassa L. Ghidini M, et al. Among authors: bozzarelli s. Cancer Med. 2016 Feb;5(2):256-64. doi: 10.1002/cam4.592. Epub 2015 Dec 29. Cancer Med. 2016. PMID: 26715198 Free PMC article.
Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications.
Personeni N, Baretti M, Bozzarelli S, Spaggiari P, Rubino L, Tronconi MC, Fumagalli Romario U, Rosati R, Giordano L, Roncalli M, Santoro A, Rimassa L. Personeni N, et al. Among authors: bozzarelli s. Gastric Cancer. 2017 May;20(3):428-437. doi: 10.1007/s10120-016-0625-1. Epub 2016 Aug 16. Gastric Cancer. 2017. PMID: 27530622
41 results